CADTH Canadian drug expert committee recommendation: Cabotegravir tablets, cabotegravir extended-release injectable suspension and rilpivirine extended-release injectable suspension (Vocabria, Cabenuva -- VIIV Healthcare ULC) indication : HIV-1 infection

Cabotegravir injection with rilpivirine injection is being indicated as a complete regimen for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in patients who are virologically stable and suppressed (HIV-1 RNA less than 50copies/mL)

Bibliographic Details

Corporate Authors:	CADTH Canadian Drug Expert Committee, Canadian Agency for Drugs and Technologies in Health
Format:	eBook
Language:	English
Published:	Ottawa (ON) Canadian Agency for Drugs and Technologies in Health September 9, 2020, 2020
Edition:	Version: 1.1
Series:	CADTH common drug review
Online Access:	https://www.ncbi.nlm.nih.gov/books/NBK566624
Collection:	National Center for Biotechnology Information - Collection details see MPG.ReNa